T1	Premise 45 176	55-year-old woman with type 1 diabetes diagnosed at age 15 years who refers nausea and abdominal distention, especially after meals
T2	Premise 178 230	Evaluation is consistent with diabetic gastroparesis
T3	Claim 335 347	Lansoprazole
T4	Claim 352 363	Ondansetron
T5	Claim 368 378	Loperamide
T6	Claim 383 397	Metoclopramide
T7	Claim 424 557	It was approved as a treatment for gastroparesis by the US Food and Drug Administration (FDA) in 1979 and remains the first-line drug
T8	Claim 559 800	It acts as a prokinetic by its antagonistic effect on dopamine 2 (D2) receptors promoting gastric emptying and, in addition, binds to the 5-hydroxytryptamine 4 receptor (serotonin 5-HT4) to stimulate cholinergic nerve pathways in the stomach
T9	Claim 802 1006	Physiologically, it accelerates intestinal transit by increasing the tone and amplitude of gastric contractions, increases lower esophageal sphincter pressure and improves antropyloroduodenal coordination
T10	Claim 1008 1122	In addition, this antiemetic agent provides relief through antagonism of central and peripheral dopamine receptors
R1	Support Ent1:T10 Ent2:T6	
R2	Support Ent1:T9 Ent2:T6	
R3	Support Ent1:T8 Ent2:T6	
R4	Support Ent1:T7 Ent2:T6	
T11	Treatment 335 347	Lansoprazole
T12	Treatment 352 363	Ondansetron
T13	Treatment 368 378	Loperamide
T14	Treatment 383 397	Metoclopramide
